Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes

European Respiratory Journal

Volumn 10, Issue 5, 1997, Pages 1130-1136

  Schuler P ^a   Zemper, K ^a   Borner, K ^b   Koeppe, P ^b   Schaberg, T ^a   Lode, H ^a  

^a Chest Hospital Heckeshorn   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

alveolar macrophages; ciprofloxacin; epithelial lining fluid; peripheral polymorphonuclear leucocytes; sparfloxacin

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0343289637     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10051130     Document Type: Article

References (49)

1. Canton A, Pemán J, Jiminez MT, Ramón MS, Gobernado M. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 1992; 36: 558-565.
2. Cooper MA, Andrews JM, Ashby JP, Matthews RS, Wise R. In vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother 1990; 26: 667-676.
3. Malmborg A-S, Ahlén S. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens. Chemotherapy 1993; 39: 32-35.
4. Simor AE, Fuller SA, Low DE. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob Agents Chemother 1990; 34: 2283-2286.
5. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, WIN 57273, ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 856-859.
6. Focht J, Nösner K, Kresken M. Sensitivity of community- and hospital-acquired bacterial isolates to sparfloxacin in comparison with other antibiotics. Drugs 1993; 45 (Suppl. 3): 152-156.
7. Wexler HM, Molitoris E, Finegold SM. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother 1992; 36: 239-243.
8. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 682-683.
9. Kenny GE, Cartwright FD. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline and erythromycin. Antimicrob Agents Chemother 1991; 35: 587-589.
10. Nakamura S, Minami A, Nakata K, et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad spectrum quinolone. Antimicrob Agents Chemother 1989; 33: 1167-1173.
11. Honeybourne D, Greaves I, Baldwin DR, Andrews JM, Harris M, Wise R. The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int J Antimicrob Agents 1994; 4: 151-155.
12. Johnson, JH, Cooper MA, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 1992; 36: 2444-2446.
13. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993; 25: 358-369.
14. Trautmann M, Ruhnke M, Borner K, Wagner J, Koeppe P. Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob Agents Chemother 1996; 40: 776-779.
15. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992; 36: 1171-1175.
16. Tulkens MP. Intracellular pharmacokinetics and localisation of antibiotics and their efficacy against intracellular infections. Scand J Infect Dis 1991; 74: 209-217.
17. Reynolds HY. Bronchoalveolar lavage. In: Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. New York, W.B. Saunders Co., 1988; pp. 597-610.
18. Schaberg T, Haller H, Rau M, Kaiser D, Fassbender M, Lode H. Superoxide anion release induced by plateletactivating factor is increased in human alveolar macrophages from smokers. Eur Respir J 1992; 5: 387-393.
19. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; 21 (Suppl. 97): 77-89.
20. Reeves DS, Bywater MJ. Assay of antimicrobial agents. In: de Louvois, ed. Selected Topics in Clinical Bacteriology. London, Bailliere Tyndall, 1976; pp. 21-55.
21. Theodore WM, Merill WW, Rankin JA, Reynolds HY. Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis 1987; 135: 1276-1280.
22. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532-538.
23. Maderazo EG, Breaux SP, Woronick CL, Quantiliani R, Nightingale CH. High teicoplanin uptake by human neutrophils. Chemotherapy 1988; 34: 248-255.
24. Schwarz G. Estimating the dimension of a model. Ann Statistics 1978; 6: 461-464.
25. Koeppe P, Hamann C. A program for nonlinear regression analysis to be used on desk-top computers. Comput Progr Biomed 1980; 12: 121-128.
26. Peck CC, Sheiner LB, Nicols AI. The problem of choosing weights in nonlinear analysis of pharmacokinetic data. Drug Metab Rev 1984; 15: 133-148.
27. Wilcoxon F, Wilcox RA. In: Some Rapid Approximate Statistical Procedures. Lederle Laboratoires, Pearl River, New York 1964; pp. 13-27.
28. Örtqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990; 3: 1105-1113.
29. Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307-316.
30. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients in the United States during the winter months of 1994 to 1995: results of a 30 center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-1213.
31. Baquero F. Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microb Drug Res 1995; 1: 115-120.
32. Jacobs RF, Kaplan SL, Schutze GE, et al. Relationship of MICs to efficacy of cetotaxime in treatment of Streptococcus pneumoniae infections. Antimicrob Agents Chemother 1996; 40: 895-898.
33. Barry B, Gehanno P, Blumen M, Boucot I. Clinical outcome of acute otitis media caused by pneumococci with decreased susceptibility to penicillin. Scand J Infect Dis 1994; 26: 446-452.
34. Reinert RR, Queck A, Kaufhold A, Kresken M, Lütticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany. Clin Infect Dis 1995; 21: 398-401.
35. Thys JP, Jacobs F, Byl B. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur J Clin Microb Infect Dis 1991; 10: 304-315.
36. Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbation of chronic bronchitis. Eur J Clin Microb Infect Dis 1986; 5: 226-231.
37. Cooper B, Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989; 87: 475-478.
38. Azoulay-Dupuis E, Vallee E, Veber B, Bedos JP, Bauchet J, Pocidalo J-J. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 1992; 36: 2698-2703.
39. Nakata K, Okazaki Y, Hattori H, Nakamura S. Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice. Antimicrob Agents Chemother 1994; 38: 1757-1762.
40. Nakata K, Maeda H, Fuji A, Arakawa S, Umezu K, Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones and tetracyclines against Chlamydia trachomatis. Antimicrob Agents Chemother 1992; 36: 188-190.
41. Wiedemann B, Kratz B, Steines A. Comparative study on the pharmacodynamic activity of sparfloxacin and ciprofloxacin in an in vitro model with S. pneumoniae. 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 1993; Abstract No. 714.
42. Wise R, Honeybourne D. Antibiotic penetration into the respiratory tract: a basis for rational therapy. Chemotherapy 1995; 4: 28-32.
43. Kucers A, Bennet MMcK. The Use of Antibiotics: Ciprofloxacin. 4th Edn. London, William Heinemann Medical Books, 1987; pp. 1248-1263.
44. Vance BK, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434-461.
45. Garcia I, Pascual A, Guzman MC, Perea EJ. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leucocytes and tissue culture cells. Antimicrob Agents Chemother 1992; 36: 1053-1056.
46. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996; 37 (Suppl. A): 57-63.
47. Miyamoto R, Matsumoto J, Chiba K, et al. Synthesis and structure activity relationships of 5 substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. J Med Chem 1990; 33: 1645-1656.
48. Lode H, Garau J, Grassi C, Hosie J, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
49. Lipsky BA, Dorr MB, Magner DJ, Talbot GH. Safety profile of sparfloxacin in North American phase III clinical trials. 36th ICAAC, New Orleans, Louisiana, 1996; No. L013.